This is the first tender which BIOCAD has won in Syria. After being awarded the tender, the biotechnology company BIOCAD intends to begin the registration process of Trastuzumab in Syria, with the help of the Fast Track mechanism (an accelerated pharmaceutical review program).
Another of BIOCAD’s pharmaceuticals is currently at the registration stage in Syria, the biosimilar Rituximab. This is the first Russian monoclonal antibody pharmaceutical, which is used to treat hematologic malignancies (non-Hodgkin’s lymphoma and chronic lymphocytic leukemia).
Over the next 5 years, the company is expecting to deliver more than 250 million rubles’ worth of this pharmaceutical to Syria. It is assumed that the registration process for the biosimilar Rituximab will be completed at the beginning of the third quarter of 2017.
“This is not just a tender won, but a great step forward. It is difficult for every government to be the first, therefore, when we enter a country’s market, a chain reaction occurs,” said Dmitry Morozov, CEO and founder of BIOCAD. “The pool of Arab countries with which we intend to begin working is a gigantic one.” We already cooperate with Yemen, and we are interested in future activity in the markets of Algeria, Lebanon, Iraq and Iran.”